Kayentis has announced it is forging ahead on five new eCOA service projects with Emerging BioPharma companies. The projects Kayentis is collaborating on involve phase II and III clinical studies in therapeutic areas addressing unmet needs in areas like oncology, immune disorders, and rare diseases. In response to COVID-19, Kayentis has implemented a dedicated contingency plan for sites and patients to keep trials running.
For more information, click here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access